J.M. Extra

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

p53 mutations and overexpression in locally advanced breast cancers

A Faille, Patricia de Crémoux, J.M. Extra et al. · British Journal of Cancer · 1994 · 72 citations · Full text

Breast Oncology, P53 Mutations, Medicine +6

Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80).

Bertrand Coiffier, P.A. Bryon, F Berger et al. · Journal of Clinical Oncology · 1986 · 71 citations

Pathology, Pharmacotherapy, Metronomic Chemotherapy +21

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

Véronique Dièras, J.M. Extra, Éric Bellissant et al. · Journal of Clinical Oncology · 1996 · 69 citations

Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.

P. Fumoleau, T. Delozier, J.M. Extra et al. · PubMed · 1995 · 43 citations